<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Summit Therapeutics Plc — News on 6ix</title>
<link>https://6ix.com/company/summit-therapeutics-plc</link>
<description>Latest news and press releases for Summit Therapeutics Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 27 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/summit-therapeutics-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c1ac78dffbe2df11900d.webp</url>
<title>Summit Therapeutics Plc</title>
<link>https://6ix.com/company/summit-therapeutics-plc</link>
</image>
<item>
<title>Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/multiple-ivonescimab-data-sets-from-phase-iii-studies-in-advanced-nsclc-patient-populations-to-be-featured-at-elcc-2026</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/multiple-ivonescimab-data-sets-from-phase-iii-studies-in-advanced-nsclc-patient-populations-to-be-featured-at-elcc-2026</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study</description>
</item>
<item>
<title>Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-fourth-quarter-and-year-ended-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-reports-financial-results-and-operational-progress-for-the-fourth-quarter-and-year-ended-december-31-2025</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>MIAMI, February 23, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and year ended December 31, 2025.</description>
</item>
<item>
<title>Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-host-fourth-quarter-220500570</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-host-fourth-quarter-220500570</guid>
<pubDate>Tue, 17 Feb 2026 22:05:00 GMT</pubDate>
<description>MIAMI, February 17, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes.</description>
</item>
<item>
<title>Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-u-fda-123000277</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-u-fda-123000277</guid>
<pubDate>Thu, 29 Jan 2026 12:30:00 GMT</pubDate>
<description>MIAMI, January 29, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) post-tyrosine kinase inhibitor (TKI) therapy. The FDA prov</description>
</item>
<item>
<title>Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-clinical-trial-collaboration-gsk-evaluate-ivonescimab</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-clinical-trial-collaboration-gsk-evaluate-ivonescimab</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Summit to Advance Development Opportunities of Ivonescimab with GSK’s Novel B7-H3 risvutatug rezetecan Multiple Solid Tumor Settings to Be Pursued with</description>
</item>
<item>
<title>Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-submission-biologics-license-application-bla-us-fda</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-submission-biologics-license-application-bla-us-fda</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Significant Unmet Need Remains in this Setting Over 14,000 Patients are Eligible for 2L+ Treatment in This Setting in the United States Each Year Summit</description>
</item>
<item>
<title>Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-reports-inducement-grants-011600793</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-reports-inducement-grants-011600793</guid>
<pubDate>Sat, 10 Jan 2026 01:16:00 GMT</pubDate>
<description>MIAMI, January 10, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock. Awards were made to seventeen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Co</description>
</item>
<item>
<title>Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-present-44th-annual-123000758</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-present-44th-annual-123000758</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>MIAMI, January 06, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present...</description>
</item>
<item>
<title>Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/ivonescimab-plus-chemotherapy-demonstrates-statistically-140000028</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/ivonescimab-plus-chemotherapy-demonstrates-statistically-140000028</guid>
<pubDate>Fri, 07 Nov 2025 14:00:00 GMT</pubDate>
<description>MIAMI, November 07, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today noted that our partner, Akeso, Inc. ("Akeso," HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor,</description>
</item>
<item>
<title>Summit Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-present-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-present-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present</description>
</item>
<item>
<title>Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/overall-survival-data-harmoni-featuring-ivonescimab-combination-chemotherapy-vs</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/overall-survival-data-harmoni-featuring-ivonescimab-combination-chemotherapy-vs</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen</description>
</item>
<item>
<title>Summit Therapeutics Raises $500 Million in Private Placement</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-raises-500-million-private-placement-2025-10-22</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-raises-500-million-private-placement-2025-10-22</guid>
<pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
<description>Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday’s Closing Price of $18.74</description>
</item>
<item>
<title>Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-reports-financial-results-and-operational-progress-third-quarter</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-reports-financial-results-and-operational-progress-third-quarter</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Summit Plans to Submit a BLA in Q4 2025 for Ivonescimab Based on HARMONi Global Phase III Study Results Expansion of Summit’s Global Phase III Development</description>
</item>
<item>
<title>Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/ivonescimab-chemotherapy-reduced-risk-disease-143000929</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/ivonescimab-chemotherapy-reduced-risk-disease-143000929</guid>
<pubDate>Sun, 19 Oct 2025 14:30:00 GMT</pubDate>
<description>MIAMI, October 19, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany.</description>
</item>
<item>
<title>Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-expansion-ivonescimab-global-phase-iii-development</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-announces-expansion-ivonescimab-global-phase-iii-development</guid>
<pubDate>Fri, 17 Oct 2025 04:00:00 GMT</pubDate>
<description>HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLC Clinical Trial Site Activations Planned to Begin This</description>
</item>
<item>
<title>Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-host-esmo-data-update-third-quarter-earnings-call-october-20-2025</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-host-esmo-data-update-third-quarter-earnings-call-october-20-2025</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference Call to be Held at 8:00am ET MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an ESMO</description>
</item>
<item>
<title>HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/harmoni-6-featuring-ivonescimab-combined-110000495</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/harmoni-6-featuring-ivonescimab-combined-110000495</guid>
<pubDate>Wed, 24 Sep 2025 11:00:00 GMT</pubDate>
<description>MIAMI, September 24, 2025--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be featured as part of the Presidential Symposium at the European Society for Medical Oncology 2025 Congress (ESMO 2025) which takes place from October</description>
</item>
<item>
<title>Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/ivonescimab-plus-chemotherapy-demonstrates-consistent-global-benefit-harmoni-data</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/ivonescimab-plus-chemotherapy-demonstrates-consistent-global-benefit-harmoni-data</guid>
<pubDate>Sun, 07 Sep 2025 04:00:00 GMT</pubDate>
<description>The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332In the North American patients, the OS HR was</description>
</item>
<item>
<title>Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/longer-term-follow-western-patients-showed-improving-favorable-trend-overall-survival</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/longer-term-follow-western-patients-showed-improving-favorable-trend-overall-survival</guid>
<pubDate>Sun, 07 Sep 2025 04:00:00 GMT</pubDate>
<description>With Longer-Term Follow-Up of Western Patients, Ivonescimab Plus Chemotherapy Demonstrated Improving Global OS Trend with Nominal p-value of 0.0332 vs.</description>
</item>
<item>
<title>Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025</title>
<link>https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-host-update-call-wclc-2025-september-8-2025-2025-09-03</link>
<guid isPermaLink="true">https://6ix.com/company/summit-therapeutics-plc/news/summit-therapeutics-host-update-call-wclc-2025-september-8-2025-2025-09-03</guid>
<pubDate>Wed, 03 Sep 2025 04:00:00 GMT</pubDate>
<description>Leadership to Discuss Full Presentation Data from HARMONi, the Global Phase III Clinical Trial Featured in the Presidential Symposium at WCLC 2025</description>
</item>
</channel>
</rss>